Search results for "Nuclear matrix protein"

showing 3 items of 3 documents

Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell c…

2005

ABSTRACT Purpose: We developed and validated nomograms that accurately predict disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma (TCC) of the bladder using a large international cohort. Methods: Univariate and multivariate logistic regression models targeted histologically confirmed disease recurrence, and focused on 2,542 patients with bladder TCC from 10 participating centers. Variables consisted of pre-cystoscopy voided urine Nuclear Matrix Protein 22 (NMP22) assay, urine cytology, age and gender. Resulting nomograms were internally validated with bootstrapping. Nomogram performance was explored graphically with Loess smoothing plots. Results:…

AdultMalemedicine.medical_specialtyAdolescentUrologyUrinary systemUrologyurologic and male genital diseasesLogistic regressionBladder neoplasmsnuclear matrix protein 22neoplasm stagingnomogramsBladder NeoplasmCytologyBiomarkers TumormedicineHumansStage (cooking)AgedNeoplasm StagingUrine cytologyAged 80 and overCarcinoma Transitional Cellmedicine.diagnostic_testbusiness.industryNuclear ProteinsMiddle AgedNomogramPrognosismedicine.diseasefemale genital diseases and pregnancy complicationsSurgeryNomogramsTransitional cell carcinomaUrinary Bladder NeoplasmsMultivariate AnalysisDisease ProgressionFemalebusiness
researchProduct

Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.

2006

PURPOSE: We assessed variability in the diagnostic performance of NMP22 for detecting recurrence and progression in patients with Ta, T1, and/or CIS transitional cell carcinoma of the bladder in a large international cohort. MATERIALS AND METHODS: NMP22 voided urine levels were measured in 2,871 patients who underwent office cystoscopy for monitoring previous stage Ta, T1 and/or CIS transitional cell carcinoma at 12 participating institutions. RESULTS: Patient characteristics varied considerably among institutions. Overall 1,045 patients (36.4%) had recurrent transitional cell carcinoma (range across institutions 13.6% to 54.3%). Median NMP22 was 5.5 U/ml (range across institutions 2.5 to 1…

AdultMalemedicine.medical_specialtyUrologyUrinary systemnuclear matrix protein 22Urologytumor markers biologicalBladder NeoplasmBiomarkers TumorMedicineHumansStage (cooking)bladderAgedGynecologyAged 80 and overCarcinoma Transitional CellUrinary bladderBladder cancermedicine.diagnostic_testbusiness.industryCarcinoma in situNuclear ProteinsReproducibility of ResultsCystoscopyMiddle Agedmedicine.diseasemedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsDisease Progressionbladder neoplasmFemaleNeoplasm Recurrence LocalbusinessThe Journal of urology
researchProduct

Prognostic value of nuclear matrix protein expression in localized prostate cancer.

2012

The aim of the study was to correlate nuclear matrix (NM) protein expression profiles with the risk of PSA progression or death in early prostate cancer (PCa).High-resolution two-dimensional gel electrophoresis (2D-PAGE) was used to identify tumor-associated NM proteins in the PCa specimens obtained from 94 patients. The association between the expression of each protein and the probability of PSA progression or death was studied through univariate analysis. Unsupervised hierarchical clustering analysis was then used to generate patient clusters showing comparable outcomes by including the proteins that were predictive at univariate analysis. PSA-free and overall survival curves relative to…

OncologyPCA3MaleCancer Researchmedicine.medical_specialtyPrognosiPSA progressionValue (computer science)Kaplan-Meier EstimateNuclear matrix proteins; Prognosis Prostate cancer; PSA progressionurologic and male genital diseasesNuclear Matrix-Associated ProteinFollow-Up StudieProstate cancerNuclear Matrix-Associated ProteinsInternal medicinemedicineCluster AnalysisHumansElectrophoresis Gel Two-DimensionalNuclear matrix proteinMultivariate AnalysiProportional Hazards ModelsNuclear matrix proteinsHematologyCluster AnalysiProstate cancerProportional hazards modelbusiness.industryProstatic NeoplasmsPSA PROGRESSIONGeneral MedicineProstate-Specific AntigenNuclear matrixmedicine.diseasePrognosisProstate-specific antigenOncologyMultivariate AnalysisDisease ProgressionProportional Hazards ModelbusinessFollow-Up StudiesHuman
researchProduct